MITNEC-A1 trial sponsor

University Health Network (UHN) is Canada's largest health research organization and a premier academic medical center based in Toronto. As the official sponsor of the MITNEC-A1 clinical trial, UHN leads a significant Phase 3 multi-center study evaluating the diagnostic performance of 18F-Fluorocholine PET/CT imaging in patients with recurrent prostate cancer. The organization encompasses several world-renowned institutions, including the Princess Margaret Cancer Centre and Toronto General Hospital, and is affiliated with the University of Toronto. UHN is a global leader in medical innovation, particularly in the fields of oncology, cardiology, and transplantation, and manages an extensive portfolio of investigator-initiated and industry-sponsored clinical trials.